Developer docs
API playgroundTry for free, no card

Search company profiles

Eledon Pharmaceuticals

Full company profile

uuid00039np

Namestring
Eledon Pharmaceuticals
Legal namestring
Eledon Pharmaceuticals, Inc.
Websiteurl
eledon.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Eledon Pharmaceuticals is a clinical-stage biotechnology company developing tegoprubart, a first-in-class anti-CD40L monoclonal antibody that modulates rather than suppresses the immune system by blocking the CD40/CD40L costimulatory pathway, inhibiting multiple costimulatory receptors including CD40 and CD11, and increasing polarization of lymphocytes into regulatory T cells (Tregs). The company targets the ~100,000-person U.S. kidney transplant waiting list as its primary indication — where standard-of-care calcineurin inhibitors (tacrolimus) drive a 10-12 year average functional lifespan and significant toxicity — and is also developing tegoprubart across islet cell transplantation for Type 1 diabetes (FDA Orphan Drug Designation), liver transplantation (FDA Orphan Drug Designation, March 2026), xenotransplantation programs (kidney via eGenesis; heart via United Therapeutics, MGH, UMD), and a Phase 2-completed ALS program.

Eledon's lead asset has demonstrated differentiated clinical performance versus tacrolimus, including a mean eGFR of 74 versus 61 mL/min/1.73 m² at 18 months in the Phase 2 BESTOW kidney transplant trial and zero biopsy-proven acute rejection events after six months in the tegoprubart arm versus seven in the tacrolimus arm. In an investigator-sponsored islet cell transplant trial at UChicago Medicine, 12 of 12 type 1 diabetes patients achieved insulin independence with mean HbA1c of ~5.4% on a tegoprubart-based regimen. The company is pre-revenue, with no approved products or pricing models; operations are funded through equity financings, including a $50M oversubscribed private placement led by BVF Partners LP (May 2024) and a $50M underwritten public offering led by Leerink Partners and Cantor Fitzgerald (November 2025), with $111.1M in cash, equivalents, and short-term investments as of March 31, 2026, expected to fund operations into Q2 2027.

The business model centers on advancing tegoprubart through clinical development, securing regulatory designations, and building a network of strategic partnerships with transplant centers and biopharma collaborators (NewcelX, eGenesis, United Therapeutics, Mass General, UChicago Medicine) that validate the platform across indications. A planned Phase 3 registrational trial in kidney transplantation is targeted for late 2026 following an FDA End-of-Phase 2 meeting, with future commercial launch envisioned through specialty pharma channels targeting transplant centers. Tegoprubart (formerly AT-1501) originated from research partly funded by Augie's Quest to Cure ALS and is protected by FDA Orphan Drug Designations in two indications, positioning the company as a potential first-mover in the anti-CD40L antibody class for transplantation.

Short descriptiontext

Eledon Pharmaceuticals is a clinical-stage biotechnology company developing tegoprubart, a first-in-class anti-CD40L monoclonal antibody being advanced across kidney, liver, islet cell, and xenotransplantation indications to address immune-mediated rejection and calcineurin inhibitor toxicity in organ and cellular transplant recipients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceuticals, immunosuppressive antibody therapy, organ transplant therapeutics, anti-CD40L antibody, monoclonal antibody development
Industry3 codes
PRIMARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Transplant Immunology Therapeutics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-revenue clinical development
TypeSubscription Recurring
Description

Eledon is a clinical-stage biotechnology company with no commercial product revenue. Operations are funded by equity financings (public offerings, private placements) and research collaborations. The company is not yet generating product revenue; tegoprubart is in clinical trials and has not been approved or commercialized.

eledon.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Not applicable — clinical-stage investigational therapy, no commercial pricing
ModelOtherBilling cadencePay-as-you-go
Notes

No pricing has been publicly disclosed. Tegoprubart is an investigational anti-CD40L antibody in clinical development, not yet approved by the FDA or any regulatory authority.

eledon.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Eledon Pharmaceuticals is a clinical-stage biotechnology company developing tegoprubart, an investigational anti-CD40L monoclonal antibody, for the prevention of allograft rejection in organ and cellular transplantation. The lead program targets kidney transplantation (Phase 2 BESTOW completed, Phase 3 planned) with additional programs in islet cell transplantation for Type 1 diabetes, liver transplantation, xenotransplantation, and ALS. The company is pre-revenue and not yet commercially selling any approved product.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Mean eGFR of 74 mL/min/1.73 m² for tegoprubart vs. 61 mL/min/1.73 m² for tacrolimus at 18 months in Phase 2 BESTOW kidney transplant trial (p<0.05)
+4 more records
Product overview1 text field

Eledon Pharmaceuticals is a clinical-stage biotechnology company built around a single lead investigational product, tegoprubart, an anti-CD40L antibody — rather than a platform-plus-modules architecture. Tegoprubart serves as the cornerstone of Eledon's pipeline and is being developed across multiple transplant indications (kidney allotransplantation via the completed Phase 2 BESTOW trial and ongoing Phase 1b/extension studies, islet cell transplantation in Type 1 diabetes with FDA Orphan Drug Designation, liver transplantation with FDA Orphan Drug Designation, and kidney tolerance) as well as xenotransplantation programs (eGenesis-sponsored Phase 1/2/3 kidney study, adult heart under FDA Expanded Access Protocol, and pediatric heart) and a neurodegenerative disease program in amyotrophic lateral sclerosis (ALS). The company's product strategy is to leverage its immunology expertise around the CD40/CD40L pathway to address a single underlying mechanism — immune-mediated rejection and dysregulated immune response — across this portfolio of tegoprubart programs.

Product and service7 records
1Tegoprubart
CategoryAnti-CD40L monoclonal antibody (investigational therapy)
Description

Tegoprubart is Eledon's lead investigational anti-CD40L monoclonal antibody with high affinity for CD40 Ligand (CD40L/CD154). It blocks the CD40/CD40L co-stimulatory immune pathway, inhibits multiple costimulatory receptors including CD40 and CD11, and increases polarization of lymphocytes into regulatory T cells (Tregs), creating a tolerogenic environment to prevent organ transplant rejection without the lymphopenia associated with many immunosuppressive drugs.

2Tegoprubart — Kidney Transplantation Program
CategoryCore pipeline indication (allotransplantation)
Description

Completed global Phase 2 BESTOW trial comparing tegoprubart versus tacrolimus for prevention of rejection in first-time kidney allograft recipients, plus ongoing Phase 1b and Long-Term Extension trials. Participants completing BESTOW are eligible to enroll in an ongoing global open-label extension study evaluating long-term efficacy and safety.

3Tegoprubart — Islet Cell Transplantation Program
CategoryCore pipeline indication (allotransplantation, Type 1 diabetes)
Description

Investigator-sponsored trials at the University of Chicago evaluating tegoprubart as part of an immunosuppression regimen following islet cell transplantation in Type 1 diabetes patients. Has received U.S. FDA Orphan Drug Designation. A multi-site investigator-sponsored trial is also evaluating tegoprubart in islet cell transplantation in patients with impaired renal function.

4Tegoprubart — Liver Transplantation Program
CategoryCore pipeline indication (allotransplantation)
Description

IND-ready liver transplantation program. Tegoprubart received FDA Orphan Drug Designation for preventing allograft rejection in liver transplantation, with Eledon planning to initiate a clinical trial.

5Tegoprubart — Xenotransplantation Programs
CategoryCore pipeline indication (xenotransplantation)
Description

Xenotransplantation programs include the eGenesis-sponsored Phase 1/2/3 study in kidney xenotransplantation. Additional adult heart procedures have been performed under U.S. FDA Expanded Access Protocol (EAP), and a pediatric heart program is also in development. Tegoprubart has been used in landmark pig kidney transplants at Massachusetts General Hospital and a pig heart transplant at the University of Maryland Medical Center.

6Tegoprubart — Kidney Tolerance Program
CategoryPipeline indication (allotransplantation)
Description

Massachusetts General Hospital investigator-sponsored trial evaluating tegoprubart in kidney tolerance induction.

7Tegoprubart — ALS (Amyotrophic Lateral Sclerosis) Program
CategoryPipeline indication (neurodegenerative disease)
Description

Eledon has successfully completed a Phase 2, dose-ranging, biomarker study in amyotrophic lateral sclerosis (ALS). The company is seeking non-equity dilutive financing to advance the program to Phase 3.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-06-01
Description

Investigator-sponsored Phase 2 islet cell transplantation trial of tegoprubart in type 1 diabetes patients at UChicago Medicine Transplant Institute (Dr. Piotr Witkowski). Trial funded by Breakthrough T1D and supported by The Cure Alliance; 12/12 patients achieved insulin independence.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-06-01
Description

Supported the investigator-initiated Phase 2 islet cell transplant trial of tegoprubart in type 1 diabetes patients at the University of Chicago Medicine Transplant Institute.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-01
Description

NewcelX and Eledon announced a strategic research collaboration to advance the NCEL-101 program for Type 1 Diabetes, integrating Eledon's anti-CD40L monoclonal antibody tegoprubart with NewcelX's stem-cell-derived NCEL-101 islet therapy. The collaboration aims to support durable islet graft survival and streamline regulatory pathways, leveraging extensive transplant experience.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-01
Description

Eledon is supporting global xenotransplant collaborations with United Therapeutics, providing tegoprubart as the immunosuppression backbone for xenotransplantation programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

eGenesis-sponsored Phase 1/2/3 study of tegoprubart in xenotransplantation (gene-edited pig kidney transplants). Eledon supports eGenesis' pig-to-human kidney xenotransplant program with tegoprubart as the immunosuppression regimen.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-01-01
Description

Investigator-sponsored Kidney Tolerance study at Mass. General Hospital; MGH also performed the second gene-edited pig kidney xenotransplant with tegoprubart as the immunosuppression backbone.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Bristol Myers Squibb
TypeBroad incumbent
Description

BMS markets Nulojix (belatacept), a CD80/CD86 costimulation blocker approved for kidney transplant rejection prophylaxis, making it the only currently approved biologic alternative to calcineurin inhibitors in transplantation and the closest incumbent to tegoprubart's mechanism category.

TypeBroad incumbent
Description

Vertex acquired Alpine Immune Sciences, a transplant immunology company developing a first-in-class immunomodulator for kidney transplant, in 2024, making it a major pharma competitor with overlapping transplant-immunology ambitions and substantially greater resources.

TypeBroad incumbent
Description

Pfizer (legacy Wyeth/Hospira) markets sirolimus/rapamycin and other transplant immunosuppressants, and has a long history in transplant therapeutics — making it a broad incumbent that competes in the same prescriber and patient population tegoprubart would target.

TypeBroad incumbent
Description

Sanofi markets CellCept (mycophenolate mofetil), a widely used transplant immunosuppressant, and also acquired Provention Bio for $2.9B. Director Jan Hillson's prior role there highlights Sanofi's deep ties to the transplant and immunology commercial channels Eledon must engage.

TypeDirect peer
Description

Veloxis (an Asahi Kasei company) is a transplant-focused specialty pharma best known for Envarsus XR, a once-daily tacrolimus formulation. It is the most direct competitor in transplant immunosuppression with overlapping prescribers (transplant centers) and a head-to-head competitive dynamic with tegoprubart.

TypeDirect peer
Description

United Therapeutics is a leader in xenotransplantation (e.g., Revivicor/UKidney) and has a strategic collaboration with Eledon to use tegoprubart as the immunosuppression backbone for its xenotransplant programs, making it a co-developer in the same clinical and commercial pathway.

TypeEmerging player
Description

Sangamo is developing zinc-finger nuclease gene-editing approaches for transplant tolerance, including donor-derived cell therapy programs that could compete with tegoprubart's Treg-polarizing mechanism in the transplant immunology space.

TypeDirect peer
Description

eGenesis is developing gene-edited pig organs for xenotransplantation and is Eledon's strategic partner in running the tegoprubart-based immunosuppression regimen in their Phase 1/2/3 xenotransplant study. The companies are commercially and clinically co-dependent in xenotransplantation.

TypeOthers
Description

CareDx is a transplant-focused diagnostics company (AlloSure, AlloMap) that serves the same transplant centers and nephrologists Eledon would target with tegoprubart, making it an ecosystem peer for transplant commercial strategy even though it does not compete therapeutically.

TypeBroad incumbent
Description

Astellas markets Prograf (tacrolimus), the 30-year standard-of-care immunosuppressant that tegoprubart is being positioned to replace in kidney transplantation. Astellas is the dominant incumbent whose share tegoprubart must take to generate commercial value.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors26 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eledon Pharmaceuticals

Transplant Immunology Therapeuticseledon.com

Eledon Pharmaceuticals is a clinical-stage biotechnology company developing tegoprubart, a first-in-class anti-CD40L monoclonal antibody being advanced across kidney, liver, islet cell, and xenotransplantation indications to address immune-mediated rejection and calcineurin inhibitor toxicity in organ and cellular transplant recipients.

What Eledon Pharmaceuticals does

Eledon Pharmaceuticals is a clinical-stage biotechnology company developing tegoprubart, a first-in-class anti-CD40L monoclonal antibody that modulates rather than suppresses the immune system by blocking the CD40/CD40L costimulatory pathway, inhibiting multiple costimulatory receptors including CD40 and CD11, and increasing polarization of lymphocytes into regulatory T cells (Tregs). The company targets the ~100,000-person U.S. kidney transplant waiting list as its primary indication — where standard-of-care calcineurin inhibitors (tacrolimus) drive a 10-12 year average functional lifespan and significant toxicity — and is also developing tegoprubart across islet cell transplantation for Type 1 diabetes (FDA Orphan Drug Designation), liver transplantation (FDA Orphan Drug Designation, March 2026), xenotransplantation programs (kidney via eGenesis; heart via United Therapeutics, MGH, UMD), and a Phase 2-completed ALS program.

Eledon's lead asset has demonstrated differentiated clinical performance versus tacrolimus, including a mean eGFR of 74 versus 61 mL/min/1.73 m² at 18 months in the Phase 2 BESTOW kidney transplant trial and zero biopsy-proven acute rejection events after six months in the tegoprubart arm versus seven in the tacrolimus arm. In an investigator-sponsored islet cell transplant trial at UChicago Medicine, 12 of 12 type 1 diabetes patients achieved insulin independence with mean HbA1c of ~5.4% on a tegoprubart-based regimen. The company is pre-revenue, with no approved products or pricing models; operations are funded through equity financings, including a $50M oversubscribed private placement led by BVF Partners LP (May 2024) and a $50M underwritten public offering led by Leerink Partners and Cantor Fitzgerald (November 2025), with $111.1M in cash, equivalents, and short-term investments as of March 31, 2026, expected to fund operations into Q2 2027.

The business model centers on advancing tegoprubart through clinical development, securing regulatory designations, and building a network of strategic partnerships with transplant centers and biopharma collaborators (NewcelX, eGenesis, United Therapeutics, Mass General, UChicago Medicine) that validate the platform across indications. A planned Phase 3 registrational trial in kidney transplantation is targeted for late 2026 following an FDA End-of-Phase 2 meeting, with future commercial launch envisioned through specialty pharma channels targeting transplant centers. Tegoprubart (formerly AT-1501) originated from research partly funded by Augie's Quest to Cure ALS and is protected by FDA Orphan Drug Designations in two indications, positioning the company as a potential first-mover in the anti-CD40L antibody class for transplantation.

Eledon Pharmaceuticals firmographics

Firmographics
Name
Eledon Pharmaceuticals
Legal name
Eledon Pharmaceuticals, Inc.
Website
https://eledon.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Eledon Pharmaceuticals is a clinical-stage biotechnology company developing tegoprubart, a first-in-class anti-CD40L monoclonal antibody being advanced across kidney, liver, islet cell, and xenotransplantation indications to address immune-mediated rejection and calcineurin inhibitor toxicity in organ and cellular transplant recipients.
Ownership category
akta.pro rank

Eledon Pharmaceuticals industry classification

Industry
Product category
Transplant Immunology Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Clinical-stage biopharmaceuticals
  • Immunosuppressive antibody therapy
  • Organ transplant therapeutics
  • Anti-CD40L antibody
  • Monoclonal antibody development

Where Eledon Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Eledon Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pre-revenue clinical development: Eledon is a clinical-stage biotechnology company with no commercial product revenue. Operations are funded by equity financings (public offerings, private placements) and research collaborations. The company is not yet generating product revenue; tegoprubart is in clinical trials and has not been approved or commercialized.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goNot applicable — clinical-stage investigational therapy, no commercial pricing

Go-to-market motion3 records

Distribution channels3 records

Marketing channels9 records

Eledon Pharmaceuticals product offering

Product offering

Core offering

Eledon Pharmaceuticals is a clinical-stage biotechnology company developing tegoprubart, an investigational anti-CD40L monoclonal antibody, for the prevention of allograft rejection in organ and cellular transplantation. The lead program targets kidney transplantation (Phase 2 BESTOW completed, Phase 3 planned) with additional programs in islet cell transplantation for Type 1 diabetes, liver transplantation, xenotransplantation, and ALS. The company is pre-revenue and not yet commercially selling any approved product.

Product overview

Eledon Pharmaceuticals is a clinical-stage biotechnology company built around a single lead investigational product, tegoprubart, an anti-CD40L antibody — rather than a platform-plus-modules architecture. Tegoprubart serves as the cornerstone of Eledon's pipeline and is being developed across multiple transplant indications (kidney allotransplantation via the completed Phase 2 BESTOW trial and ongoing Phase 1b/extension studies, islet cell transplantation in Type 1 diabetes with FDA Orphan Drug Designation, liver transplantation with FDA Orphan Drug Designation, and kidney tolerance) as well as xenotransplantation programs (eGenesis-sponsored Phase 1/2/3 kidney study, adult heart under FDA Expanded Access Protocol, and pediatric heart) and a neurodegenerative disease program in amyotrophic lateral sclerosis (ALS). The company's product strategy is to leverage its immunology expertise around the CD40/CD40L pathway to address a single underlying mechanism — immune-mediated rejection and dysregulated immune response — across this portfolio of tegoprubart programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Tegoprubart Tegoprubart is Eledon's lead investigational anti-CD40L monoclonal antibody with high affinity for CD40 Ligand (CD40L/CD154). It blocks the CD40/CD40L co-stimulatory immune pathway, inhibits multiple costimulatory receptors including CD40 and CD11, and increases polarization of lymphocytes into regulatory T cells (Tregs), creating a tolerogenic environment to prevent organ transplant rejection without the lymphopenia associated with many immunosuppressive drugs.
  • Tegoprubart — Kidney Transplantation Program Completed global Phase 2 BESTOW trial comparing tegoprubart versus tacrolimus for prevention of rejection in first-time kidney allograft recipients, plus ongoing Phase 1b and Long-Term Extension trials. Participants completing BESTOW are eligible to enroll in an ongoing global open-label extension study evaluating long-term efficacy and safety.
  • Tegoprubart — Islet Cell Transplantation Program Investigator-sponsored trials at the University of Chicago evaluating tegoprubart as part of an immunosuppression regimen following islet cell transplantation in Type 1 diabetes patients. Has received U.S. FDA Orphan Drug Designation. A multi-site investigator-sponsored trial is also evaluating tegoprubart in islet cell transplantation in patients with impaired renal function.
  • Tegoprubart — Liver Transplantation Program IND-ready liver transplantation program. Tegoprubart received FDA Orphan Drug Designation for preventing allograft rejection in liver transplantation, with Eledon planning to initiate a clinical trial.
  • Tegoprubart — Xenotransplantation Programs Xenotransplantation programs include the eGenesis-sponsored Phase 1/2/3 study in kidney xenotransplantation. Additional adult heart procedures have been performed under U.S. FDA Expanded Access Protocol (EAP), and a pediatric heart program is also in development. Tegoprubart has been used in landmark pig kidney transplants at Massachusetts General Hospital and a pig heart transplant at the University of Maryland Medical Center.
  • Tegoprubart — Kidney Tolerance Program Massachusetts General Hospital investigator-sponsored trial evaluating tegoprubart in kidney tolerance induction.
  • Tegoprubart — ALS (Amyotrophic Lateral Sclerosis) Program Eledon has successfully completed a Phase 2, dose-ranging, biomarker study in amyotrophic lateral sclerosis (ALS). The company is seeking non-equity dilutive financing to advance the program to Phase 3.

Quantifiable outcome

  • Mean eGFR of 74 mL/min/1.73 m² for tegoprubart vs. 61 mL/min/1.73 m² for tacrolimus at 18 months in Phase 2 BESTOW kidney transplant trial (p<0.05)
  • +4 more outcomes

Companies that use Eledon Pharmaceuticals

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles2 records

Eledon Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Eledon Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • University of Chicago Medicine Transplant InstitutecoreImplementation/ SI/ Consulting Partner · 1 June 2026Investigator-sponsored Phase 2 islet cell transplantation trial of tegoprubart in type 1 diabetes patients at UChicago Medicine Transplant Institute (Dr. Piotr Witkowski). Trial funded by Breakthrough T1D and supported by The Cure Alliance; 12/12 patients achieved insulin independence.
  • The Cure AllianceminorGTM or Marketing Partner · 1 June 2026Supported the investigator-initiated Phase 2 islet cell transplant trial of tegoprubart in type 1 diabetes patients at the University of Chicago Medicine Transplant Institute.
  • NewcelX Ltd.coreStrategic or Co-development Partner · 1 March 2026NewcelX and Eledon announced a strategic research collaboration to advance the NCEL-101 program for Type 1 Diabetes, integrating Eledon's anti-CD40L monoclonal antibody tegoprubart with NewcelX's stem-cell-derived NCEL-101 islet therapy. The collaboration aims to support durable islet graft survival and streamline regulatory pathways, leveraging extensive transplant experience.
  • United TherapeuticscoreStrategic or Co-development Partner · 1 February 2026Eledon is supporting global xenotransplant collaborations with United Therapeutics, providing tegoprubart as the immunosuppression backbone for xenotransplantation programs.
  • eGenesiscoreStrategic or Co-development Partner · 1 January 2024eGenesis-sponsored Phase 1/2/3 study of tegoprubart in xenotransplantation (gene-edited pig kidney transplants). Eledon supports eGenesis' pig-to-human kidney xenotransplant program with tegoprubart as the immunosuppression regimen.
  • Massachusetts General HospitalcoreImplementation/ SI/ Consulting Partner · 1 January 2024Investigator-sponsored Kidney Tolerance study at Mass. General Hospital; MGH also performed the second gene-edited pig kidney xenotransplant with tegoprubart as the immunosuppression backbone.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Eledon Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Bristol Myers Squibb: BMS markets Nulojix (belatacept), a CD80/CD86 costimulation blocker approved for kidney transplant rejection prophylaxis, making it the only currently approved biologic alternative to calcineurin inhibitors in transplantation and the closest incumbent to tegoprubart's mechanism category.
  • Vertex Pharmaceuticals: Vertex acquired Alpine Immune Sciences, a transplant immunology company developing a first-in-class immunomodulator for kidney transplant, in 2024, making it a major pharma competitor with overlapping transplant-immunology ambitions and substantially greater resources.
  • Pfizer: Pfizer (legacy Wyeth/Hospira) markets sirolimus/rapamycin and other transplant immunosuppressants, and has a long history in transplant therapeutics — making it a broad incumbent that competes in the same prescriber and patient population tegoprubart would target.
  • Sanofi: Sanofi markets CellCept (mycophenolate mofetil), a widely used transplant immunosuppressant, and also acquired Provention Bio for $2.9B. Director Jan Hillson's prior role there highlights Sanofi's deep ties to the transplant and immunology commercial channels Eledon must engage.
  • Astellas Pharma: Astellas markets Prograf (tacrolimus), the 30-year standard-of-care immunosuppressant that tegoprubart is being positioned to replace in kidney transplantation. Astellas is the dominant incumbent whose share tegoprubart must take to generate commercial value.

Direct peers

  • Veloxis Pharmaceuticals: Veloxis (an Asahi Kasei company) is a transplant-focused specialty pharma best known for Envarsus XR, a once-daily tacrolimus formulation. It is the most direct competitor in transplant immunosuppression with overlapping prescribers (transplant centers) and a head-to-head competitive dynamic with tegoprubart.
  • United Therapeutics: United Therapeutics is a leader in xenotransplantation (e.g., Revivicor/UKidney) and has a strategic collaboration with Eledon to use tegoprubart as the immunosuppression backbone for its xenotransplant programs, making it a co-developer in the same clinical and commercial pathway.
  • eGenesis: eGenesis is developing gene-edited pig organs for xenotransplantation and is Eledon's strategic partner in running the tegoprubart-based immunosuppression regimen in their Phase 1/2/3 xenotransplant study. The companies are commercially and clinically co-dependent in xenotransplantation.

Emerging players

  • Sangamo Therapeutics: Sangamo is developing zinc-finger nuclease gene-editing approaches for transplant tolerance, including donor-derived cell therapy programs that could compete with tegoprubart's Treg-polarizing mechanism in the transplant immunology space.

Others

  • CareDx: CareDx is a transplant-focused diagnostics company (AlloSure, AlloMap) that serves the same transplant centers and nephrologists Eledon would target with tegoprubart, making it an ecosystem peer for transplant commercial strategy even though it does not compete therapeutically.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Eledon Pharmaceuticals social profiles

Digital presence

Eledon Pharmaceuticals compliance and trust

Trust signal

Compliance5 records

Eledon Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eledon Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles13 records

Eledon Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eledon Pharmaceuticals M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eledon Pharmaceuticals

What does Eledon Pharmaceuticals do?

Eledon Pharmaceuticals is a clinical-stage biotechnology company developing tegoprubart, an investigational anti-CD40L monoclonal antibody, for the prevention of allograft rejection in organ and cellular transplantation. The lead program targets kidney transplantation (Phase 2 BESTOW completed, Phase 3 planned) with additional programs in islet cell transplantation for Type 1 diabetes, liver transplantation, xenotransplantation, and ALS. The company is pre-revenue and not yet commercially selling any approved product.

Is Eledon Pharmaceuticals a public or private company?

Eledon Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Eledon Pharmaceuticals founded?

Eledon Pharmaceuticals was founded in 2017. It employs 11 to 50 people.

Where is Eledon Pharmaceuticals based?

Eledon Pharmaceuticals is headquartered in Irvine, United States, in the North America region.

How does Eledon Pharmaceuticals make money?

One revenue line is on record: pre-revenue clinical development.

Who are Eledon Pharmaceuticals's main competitors?

Broad incumbents on record are Bristol Myers Squibb, Vertex Pharmaceuticals, Pfizer, Sanofi and Astellas Pharma. Direct peers are Veloxis Pharmaceuticals, United Therapeutics and eGenesis. Sangamo Therapeutics is listed as an emerging player. CareDx is listed as an others.

Does Eledon Pharmaceuticals have an API?

No public API is recorded for Eledon Pharmaceuticals.

What industry is Eledon Pharmaceuticals in?

Eledon Pharmaceuticals's product category is Transplant Immunology Therapeutics. Its primary akta.pro industry code is HLAIACAJ, Transplant & Immunosuppression Specialty Pharmaceuticals, with a secondary code of HLAIAAAM, Nephrology & Urology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StIs Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?Eledon Pharmaceuticals reported a cash burn of $78m over the trailing twelve months, with $70m in cash and no debt, giving an 11-month runway. Its cash burn rose 17% year-over-year, and covering another year's burn would dilute shareholders by 39% of its $200m market cap.MarketScreenerEledon Pharmaceuticals, Inc. Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements In Quality Of Life And Symptom Burden With Tegoprubart Compared To Tacrolimus At American Society Of Nephrology Kidney Week 2026 Annual MeetingEledon Pharmaceuticals presented Phase 2 BESTOW trial data at ASN Kidney Week 2026, showing sustained improvements in quality of life and symptom burden with tegoprubart versus tacrolimus after kidney transplantation. Tegoprubart-treated patients maintained symptom reductions through 12 months, while tacrolimus symptoms returned to baseline, and quality-of-life scores improved by 9.0 versus 3.3 points.Stock TitanEledon to Present Kidney Trial Outcomes at Kidney WeekEledon Pharmaceuticals will present oral results from its Phase 2 BESTOW trial at Kidney Week 2026 in Denver on October 23, 2026. The presentation covers patient-reported outcomes comparing tegoprubart to tacrolimus in kidney transplant recipients. The company is developing tegoprubart, an anti-CD40L antibody for immunomodulation.AInvestEledon Rallies on Kidney-Trial Data and FDA Fast Track — the Balance Sheet Is Still the StoryEledon Pharmaceuticals shares rose about 8% after FDA Fast Track designation for its kidney-transplant drug tegoprubart and updated BESTOW data. The drug showed a 13-point eGFR advantage over tacrolimus at month 24, but the company faces a $600-patient Phase 3 trial with only $88.8M in cash, implying a potential capital raise.OcbjEledon Gains 13% on Updated Phase 2 Trial DataEledon Pharmaceuticals shares rose 13% after updated Phase 2 trial data showed tegoprubart improved kidney function and reduced rejection. The FDA granted fast track designation, and the company plans a Phase 3 trial in Q4.MarketScreenerEledon Shares Rise on Fast-Track Designation for Kidney TreatmentEledon Pharmaceuticals shares rose 13% to $3.04 after the FDA granted fast-track designation for its kidney treatment tegoprubart. The company reported no rejections in the Phase 2 trial's tegoprubart arm after six months, and it plans to start a Phase 3 trial in the fourth quarter.MorningstarEledon Shares Rise on Fast-Track Designation for Kidney TreatmentEledon Pharmaceuticals shares rose 13% to $3.04 after the FDA granted fast-track designation for its kidney treatment tegoprubart. The drug showed higher kidney function in a Phase 2 trial versus tacrolimus, and no rejections occurred in the tegoprubart arm after six months. Eledon plans to start a Phase 3 trial in the fourth quarter of this year.BioSpaceEledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation SocietyEledon presented updated long-term Phase 2 BESTOW extension data showing tegoprubart-treated kidney transplant patients maintained higher eGFR through 24 months versus tacrolimus, with a 13 mL/min/1.73 m² advantage at month 24. No rejections occurred beyond six months in the tegoprubart arm versus seven in the tacrolimus arm. The FDA granted Fast Track designation, and the Phase 3 LEGACY study is expected to start in Q4 2026.Investing.comEledon submits IND for tegoprubart islet cell transplant study By Investing.comEledon Pharmaceuticals submitted an IND to the FDA for a registrational trial of tegoprubart in type 1 diabetes patients undergoing islet cell transplantation. The company's anti-CD40L antibody is being developed as an immunosuppression therapy, with first patients enrolled in an investigator-initiated study at the University of Chicago. Eledon expects to initiate its global Phase 3 LEGACY trial in kidney transplantation in the fourth quarter of 2026.Ticker ReportEledon Pharmaceuticals (NASDAQ:ELDN) Cut to “Strong Sell” at Wall Street ZenWall Street Zen downgraded Eledon Pharmaceuticals from a sell to a strong sell rating in a report issued Sunday. The stock opened at $3.47 Friday, with a $281.97 million market cap, a -3.81 P/E ratio and a consensus "Moderate Buy" rating and $9.67 average price target. Eledon reported -$0.27 EPS for the quarter, missing the -$0.16 consensus estimate.